Latest Ratios: P/E Ratio -1.6x · EV/EBITDA N/A · ROE -72.1%. (2023–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Market Cap | $8M | $8M | — | — |
| Enterprise Value | $3M | $4M | — | — |
| P/E Ratio → | -1.56 | — | — | — |
| P/S Ratio | — | — | — | — |
| P/B Ratio | 0.60 | 0.75 | — | — |
| P/FCF | — | — | — | — |
| P/OCF | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| EV / Revenue | — | — | — | — |
| EV / EBITDA | — | — | — | — |
| EV / EBIT | — | — | — | — |
| EV / FCF | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Gross Margin | — | — | — | — |
| Operating Margin | — | — | — | — |
| Net Profit Margin | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| ROE | -72.1% | -72.1% | -128.3% | -31.9% |
| ROA | -69.8% | -69.8% | -122.1% | -25.8% |
| ROIC | -91.5% | -91.5% | -161.0% | — |
| ROCE | -71.0% | -71.0% | -129.6% | -32.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | — | — |
| Debt / EBITDA | — | — | — | — |
| Net Debt / Equity | — | -0.41 | -0.30 | -1.24 |
| Net Debt / EBITDA | — | — | — | — |
| Debt / FCF | — | — | — | — |
| Interest Coverage | -496.55 | -496.55 | — | — |
Net cash position: cash ($5M) exceeds total debt ($346699)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Current Ratio | 81.93 | 81.93 | 35.54 | 5.21 |
| Quick Ratio | 81.93 | 81.93 | 35.54 | 5.21 |
| Cash Ratio | 36.29 | 36.29 | 10.22 | 5.21 |
| Asset Turnover | — | — | — | — |
| Inventory Turnover | — | — | — | — |
| Days Sales Outstanding | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Dividend Yield | — | — | — | — |
| Payout Ratio | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Earnings Yield | — | — | — | — |
| FCF Yield | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $25M | $28M | $42M |
Insufficient capital for development
As reported in recent financial statements, Curanex's ROIC has deteriorated to -43.6% in 2026Q1, reflecting a consistent inability to generate positive returns on the capital deployed into its botanical drug development pipeline since the company's inception nearly three decades ago.
The deeply negative ROIC trend suggests that the firm is currently destroying shareholder value rather than compounding it, as R&D expenditures fail to translate into tangible clinical milestones. Investors should monitor whether this trend is structural, given the inherent difficulty of botanical drug standardization, or if it represents a temporary phase of heavy investment.
Based on the 2026Q1 balance sheet, the company's current ratio of 62.87 appears artificially high due to the lack of current liabilities, yet the absolute cash balance of $4.97 million suggests a precarious runway for a firm engaged in high-cost clinical trials.
While the high current ratio might initially appear to signal strength, it masks the reality that the company lacks the operational scale to support its ongoing research activities. The rapid decline in cash reserves warrants further investigation into the firm's ability to sustain operations without immediate external financing or dilutive equity raises.
According to reported figures, Curanex maintains a low debt-to-equity ratio of 0.04%, which, while seemingly conservative, reflects a lack of access to traditional credit markets rather than a deliberate strategy to minimize financial risk in a capital-intensive biotechnology sector.
The absence of significant debt suggests that the company is almost entirely reliant on equity financing to fund its operations, which exposes shareholders to substantial dilution risk. This capital structure appears to be a byproduct of the firm's inability to generate the cash flow necessary to service debt, rather than a sign of financial strength.
As indicated by the P/B ratio of 0.60, investors often misapply traditional valuation metrics to Curanex, failing to recognize that book value in a pre-revenue botanical biotech firm is largely irrelevant to its actual clinical or commercial potential.
Using P/B or P/E multiples for a company without commercial revenue obscures the true risk, which is the binary outcome of clinical trials and the CMC consistency of its botanical candidates. Analysts should instead focus on the cash burn rate relative to the next major regulatory milestone, as traditional valuation ratios provide little insight into the firm's long-term viability.
Includes 30+ ratios · 3 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CURX stock.
Curanex Pharmaceuticals Inc Common Stock's current P/E ratio is -1.6x. This places it at the 50th percentile of its historical range.
Curanex Pharmaceuticals Inc Common Stock's return on equity (ROE) is -72.1%. The historical average is -77.5%.
Based on historical data, Curanex Pharmaceuticals Inc Common Stock is trading at a P/E of -1.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.